CellOrigin

CellOrigin (Hangzhou) Co., Ltd. is dedicated to the research, development, and translational application of engineered pluripotent stem cells (iPSCs and ESCs) differentiated into immune cells, such as macrophages and natural killer (NK) cells. The company’s founders hail from prestigious domestic and international institutions, including Harvard University, the Massachusetts Institute of Technology (MIT), and Zhejiang University. CellOrigin has pioneered an internationally first-of-its-kind proprietary technology platform for differentiating iPSCs into innate immune cells. Through in-depth collaborations with laboratories specializing in stem cell and synthetic biology at Harvard University and MIT, the company leverages the advantages of stem cell-induced differentiation to produce monoclonal, editable, and expandable immune cells. This approach ensures the universality, efficacy, safety, and scalable manufacturing of immune cell therapy products, facilitating their broader application in tumor immunotherapy, as well as gene and cell therapies for autoimmune diseases and rare disorders.